Spots Global Cancer Trial Database for leukemia, myeloid, acute
Every month we try and update this database with for leukemia, myeloid, acute cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED) | NCT00798213 | Leukemia, Myelo... Lymphoblastic L... | SCH 727965 Gemtuzumab ozog... | 18 Years - | Merck Sharp & Dohme LLC | |
| Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors | NCT00640796 | Leukemia, Myelo... Leukemia, Lymph... Juvenile Myelom... T-cell Lymphobl... Myelodysplastic... | Haploidentical ... Chemotherapy CliniMACS | - 18 Years | St. Jude Children's Research Hospital | |
| BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment | NCT00632749 | Leukemia, Myelo... | BI 811283 (d 1 ... Cytarabine BI 811283 (d1) Cytarabine | 18 Years - | Boehringer Ingelheim | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With AML | NCT04310592 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Neoplasms by Hi... Neoplasms Immunosuppressi... Immunologic Fac... Physiological E... Alkylating Agen... Antimetabolites... Antiviral Agent... Analgesics, Non... Anti-infective ... Analgesics Peripheral Nerv... Hematologic Dis... Hematologic Neo... Leukemia in Rem... Relapsed Adult ... Refractory AML | CYNK-001 | 18 Years - 80 Years | Celularity Incorporated | |
| An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML) | NCT02775903 | Leukemia, Myelo... Myelodysplastic... | Azacitidine Durvalumab | 18 Years - | Celgene | |
| Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT02057770 | Leukemia, Myelo... | busulfan fludarabine pho... total-body irra... Stem cell trans... cyclophosphamid... tocilizumab | 18 Years - | Washington University School of Medicine | |
| A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-World | NCT04337138 | Leukemia, Myelo... | Gemtuzumab Ozog... | 18 Years - | Pfizer | |
| VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | NCT05603884 | Leukemia, Myelo... AML Stage, Adul... | Venetoclax Comb... | 60 Years - | The First Affiliated Hospital of Xiamen University | |
| Granulocyte Colony Stimulating Factor (G-CSF) After Salvage Chemotherapy in Refractory AML | NCT02427919 | Leukemia, Myelo... | G-CSF | 17 Years - 64 Years | Seoul St. Mary's Hospital | |
| Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) | NCT02715011 | Leukemia, Myelo... | JNJ-63709178 | 18 Years - | Janssen Research & Development, LLC | |
| Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant | NCT01390311 | Leukemia, Myelo... Myelodysplastic... | Azacitidine Pre-DLI Salvage... Donor Leukocyte... | 18 Years - | Washington University School of Medicine | |
| A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia | NCT04209725 | Leukemia, Myelo... | CPX-351 Quizartinib | 18 Years - 80 Years | SCRI Development Innovations, LLC | |
| A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission | NCT01632852 | Leukemia, Myelo... | CSL362 | 18 Years - | CSL Limited | |
| CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome | NCT03393611 | Myelodysplastic... Leukemia, Myelo... Leukemia, Relap... Myelodysplastic... | CPX-351 Fludarabine Melphalan Rabbit Anti-Hum... Haplo-Cord Stem... | 18 Years - 89 Years | Weill Medical College of Cornell University | |
| MB-dNPM1-TCR.1 in Relapsed/Refractory AML | NCT06424340 | Leukemia, Myelo... | MB-dNPM1-TCR.1 | 18 Years - | Miltenyi Biomedicine GmbH | |
| Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant | NCT00986804 | Leukemia, Myelo... Myelodysplastic... | Decitabine | 18 Years - | Washington University School of Medicine | |
| A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) | NCT02545283 | Leukemia, Myelo... | Cytarabine Idasanutlin Placebo | 18 Years - | Hoffmann-La Roche | |
| Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation | NCT05005299 | Leukemia, Myelo... Leukemia, Lymph... Leukemia, Lymph... Myelodysplastic... Non-hodgkin Lym... Plasma Cell Mye... | Venetoclax Fludarabine Cyclophosphamid... | 18 Years - 75 Years | Melbourne Health | |
| Haploidentical Hematopoietic Stem Cell Transplantation for Acute Leukemias | NCT02759822 | Leukemia, Myelo... Precursor Cell ... | Haploidentical ... | 1 Year - 60 Years | Instituto Nacional de Cancer, Brazil | |
| A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies | NCT05453903 | Leukemia, Myelo... | JNJ-75276617 Venetoclax (VEN... Azacitidine (AZ... Cytarabine Daunorubicin or... | 18 Years - | Janssen Research & Development, LLC | |
| Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation | NCT02117115 | Myelodysplastic... Leukemia, Myelo... Leukemia, Myelo... Multiple Myelom... | Dynamic contras... Ioversol | 20 Years - 60 Years | Washington University School of Medicine | |
| A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-World | NCT04337138 | Leukemia, Myelo... | Gemtuzumab Ozog... | 18 Years - | Pfizer | |
| Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide | NCT00850304 | Leukemia, Myelo... | Cytosar Arsenic trioxid... | 60 Years - | Tehran University of Medical Sciences | |
| A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy | NCT02677922 | Leukemia, Myelo... | AG-120 Azacitidine AG-221 | 18 Years - | Celgene | |
| A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML) | NCT02781467 | Leukemia, Myelo... | PNK-007 Cyclophosphamid... Fludarabine Human recombina... | 18 Years - 70 Years | Celularity Incorporated | |
| Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid Leukemia | NCT03335267 | Leukemia, Myelo... | CPX-351 | 60 Years - | Weill Medical College of Cornell University | |
| NLA101 in Adults Receiving High Dose Chemotherapy for AML | NCT03301597 | Leukemia, Myelo... | NLA101 Standard of Car... | 18 Years - | Nohla Therapeutics, Inc. | |
| A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy | NCT06384261 | Leukemia, Myelo... | Cusatuzumab Venetoclax Azacitidine | 18 Years - | OncoVerity, Inc. | |
| A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML) | NCT04887857 | Leukemia, Myelo... | CC-486 Venetoclax | 18 Years - | Celgene | |
| Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia | NCT05008575 | Leukemia, Myelo... | anti-CD33 CAR N... Fludarabine Cytoxan | 18 Years - 70 Years | Xinqiao Hospital of Chongqing | |
| A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy | NCT06384261 | Leukemia, Myelo... | Cusatuzumab Venetoclax Azacitidine | 18 Years - | OncoVerity, Inc. | |
| Precision Exercise in Children With Malignant Hemopathies | NCT04090268 | Leukemia, Myelo... Leukemia, B-cel... Leukemia, T Cel... Lymphoma, Hodgk... Lymphoma, Non-H... Drepanocytosis Thalassemia Maj... Adrenoleukodyst... | Sport Therapy | 2 Years - 18 Years | University of Milano Bicocca | |
| A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies | NCT00569179 | Leukemia, Myelo... Leukemia, Lymph... Myelodysplastic... Leukemia, Myelo... | CliniMACS CD34 ... | 18 Years - 65 Years | Indiana University | |
| A Long-term Follow-up Study of Patients Who Received VOR33 | NCT05309733 | Leukemia, Myelo... | VOR33 | - | Vor Biopharma | |
| Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation | NCT02117115 | Myelodysplastic... Leukemia, Myelo... Leukemia, Myelo... Multiple Myelom... | Dynamic contras... Ioversol | 20 Years - 60 Years | Washington University School of Medicine | |
| A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia | NCT02848248 | Acute Myeloid L... | SGN-CD123A | 18 Years - 74 Years | Seagen Inc. | |
| Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia | NCT05008575 | Leukemia, Myelo... | anti-CD33 CAR N... Fludarabine Cytoxan | 18 Years - 70 Years | Xinqiao Hospital of Chongqing | |
| Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML) | NCT02003573 | Leukemia, Myelo... | decitabine iv volasertib iv i... | 65 Years - | Boehringer Ingelheim | |
| A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy | NCT03298516 | Leukemia, Myelo... | DCLL9718S Azacitidine | 18 Years - | Genentech, Inc. | |
| Prophylactic Application of Donor-derived TCM After Allogeneic HSCT | NCT02758223 | Leukemia, Myelo... Myelodysplastic... | TCM allogeneic ... | 50 Years - | Wuerzburg University Hospital | |
| Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML) | NCT00822094 | Acute Myeloid L... | CPX-351 Intensive Salva... | 18 Years - 65 Years | Jazz Pharmaceuticals | |
| Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) | NCT03388749 | Leukemia, Myelo... | Liposomal Annam... | 18 Years - | Moleculin Biotech, Inc. | |
| Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy | NCT05154474 | Metastatic Canc... Cancer, Breast Cancer Colon Cancer, Rectum Cancer, Lung Cancer Ovaries Cancer Prostate Cancer, Kidney Cancer Pancreas Myeloma Myelodysplasia Leukemia, Myelo... Leukemia,Myeloi... Leukemia, Lymph... Leukemia, Lymph... | Standard | 18 Years - | Weprom | |
| A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia | NCT04209725 | Leukemia, Myelo... | CPX-351 Quizartinib | 18 Years - 80 Years | SCRI Development Innovations, LLC | |
| Risk-adapted Therapy for Primary Acute Myeloid Leukemia | NCT04687098 | Leukemia, Myelo... | Idarubicin Ara-C G-CSF Allogeneic matc... Autologous peri... Measurable resi... | 17 Years - 70 Years | Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias | |
| Cardiovascular Function in Acute Leukemia | NCT03760237 | Leukemia, Myelo... Leukemia, Lymph... Cardiotoxicity | observation onl... | 18 Years - 90 Years | Abramson Cancer Center at Penn Medicine | |
| CD34+ Transplants for Leukemia and Lymphoma | NCT05565105 | Leukemia, Myelo... Leukemia, Lymph... | Total Body Irra... Thiotepa Cyclophosphamid... Busulfan Melphalan Fludarabine | 18 Years - 74 Years | Baptist Health South Florida | |
| Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment | NCT05628623 | Leukemia, Myelo... | Cytarabine Venetoclax CPX-351 Azacitidine | 18 Years - 59 Years | Eastern Cooperative Oncology Group | |
| A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy | NCT02670044 | Leukemia, Myelo... | Cobimetinib Idasanutlin Venetoclax | 18 Years - | Hoffmann-La Roche | |
| A Long-term Follow-up Study of Patients Who Received VOR33 | NCT05309733 | Leukemia, Myelo... | VOR33 | - | Vor Biopharma | |
| Health Counseling and Exercise in Patients With Acute Leukemia - Pilot Study | NCT01557686 | Acute Leukemia | Health counseli... | 18 Years - | Universitetshospitalernes Center for Sygepleje | |
| A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes | NCT02848001 | Leukemia, Myelo... Myelodysplastic... | CC-90009 | 18 Years - | Celgene | |
| MSC and HSC Coinfusion in Mismatched Minitransplants | NCT01045382 | Leukemia, Myelo... Leukemia, Lymph... Leukemia, Myelo... Myeloproliferat... Myelodysplastic... Multiple Myelom... Leukemia, Lymph... Hodgkin's Disea... Lymphoma, Non-H... | Mesenchymal ste... Isotonic soluti... | - 75 Years | University of Liege | |
| Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy | NCT04090736 | Leukemia, Myelo... | Pevonedistat Azacitidine | 18 Years - | PETHEMA Foundation | |
| Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | NCT06001788 | AML AML With Mutate... Hematologic Mal... KMT2Ar NPM1 Mutation MLL Rearrangeme... Leukemia Acute Myeloid L... Leukemia, Myelo... Leukemia, Myelo... Acute Leukemia Neoplasms by Hi... | Ziftomenib Fludarabine Idarubicin Cytarabine Gilteritinib Granulocyte col... | 18 Years - | Kura Oncology, Inc. | |
| HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | NCT06001385 | Acute Lymphobla... Acute Myeloid L... Acute Leukemia Myelodysplastic... Chronic Myeloid... Chronic Lymphoc... Myeloproliferat... Lymphoma Chronic Myelomo... Pro-Lymphocytic... Myelofibrosis | Busulfan Fludarabine PBSC Hematopoie... Post-Transplant... Mesna Tacrolimus Mycophenolate M... Patient Reporte... Melphalan Total-body irra... Cyclophosphamid... | 18 Years - | Center for International Blood and Marrow Transplant Research | |
| Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia | NCT02665065 | Acute Myeloid L... Leukemia, Acute... Myeloid Leukemi... Leukemia, Myelo... Acute Myelogeno... Leukemia, Acute... Myelogenous Leu... AML Bone Marrow Tra... | Iomab-B Conventional Ca... HCT | 55 Years - | Actinium Pharmaceuticals | |
| Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide | NCT00850304 | Leukemia, Myelo... | Cytosar Arsenic trioxid... | 60 Years - | Tehran University of Medical Sciences | |
| BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML) | NCT03127735 | Leukemia, Myelo... | BAY1436032 | 18 Years - | Bayer | |
| Haploidentical Hematopoietic Stem Cell Transplantation for Acute Leukemias | NCT02759822 | Leukemia, Myelo... Precursor Cell ... | Haploidentical ... | 1 Year - 60 Years | Instituto Nacional de Cancer, Brazil | |
| Cladribine Dose Escalation in Conditioning Regimen Prior to Allo-HSCT for Refractory Acute Leukemia and Myelodysplastic Syndromes | NCT03235973 | Leukemia, Myelo... Leukemia, Lymph... | Fludarabine-Cla... | 18 Years - 70 Years | Institut Paoli-Calmettes | |
| Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia | NCT00906945 | Leukemia, Myelo... | G-CSF Plerixafor Mitoxantrone Etoposide Cytarabine | 18 Years - 70 Years | Washington University School of Medicine | |
| Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | NCT01898793 | Leukemia, Myelo... | Fludarabine Cyclophosphamid... Leukapheresis Cytokine-induce... IL-2 ALT-803 Peripheral bloo... Bone marrow for... | 2 Years - | Washington University School of Medicine | |
| Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant | NCT01390311 | Leukemia, Myelo... Myelodysplastic... | Azacitidine Pre-DLI Salvage... Donor Leukocyte... | 18 Years - | Washington University School of Medicine | |
| A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy | NCT02677922 | Leukemia, Myelo... | AG-120 Azacitidine AG-221 | 18 Years - | Celgene | |
| A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy | NCT03298516 | Leukemia, Myelo... | DCLL9718S Azacitidine | 18 Years - | Genentech, Inc. | |
| A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML) | NCT02781467 | Leukemia, Myelo... | PNK-007 Cyclophosphamid... Fludarabine Human recombina... | 18 Years - 70 Years | Celularity Incorporated | |
| A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes | NCT02848001 | Leukemia, Myelo... Myelodysplastic... | CC-90009 | 18 Years - | Celgene | |
| Phase I Trial to Investigate Cafusertib Hydrochloride in Combination With Low Dose Cytarabine in Chinese Patients With Acute Myeloid Leukaemia (AML) | NCT02140606 | Leukemia, Myelo... | Cafusertib Hydr... | 18 Years - | Jiangsu Hansoh Pharmaceutical Co., Ltd. | |
| A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) | NCT03833180 | Chronic Lymphoc... Mantle Cell Lym... Follicular Lymp... Marginal Zone L... Diffuse Large B... Richter Transfo... Burkitt Lymphom... Lymphoplasmacyt... T-cell Non-Hodg... Acute Lymphoid ... Acute Myeloid L... Waldenstrom Mac... | Zilovertamab ve... | 18 Years - | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| B7.1/IL-2 Leukaemia Cell Vaccine for Non-Transplant AML RFUSIN2-AML2 (NTX) | NCT02493829 | Leukemia, Myelo... Myelodysplastic... | AML Cell Vaccin... | 18 Years - | King's College London | |
| A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems | NCT03814005 | Myelodysplastic... Leukemia, Myelo... Leukemia, Myelo... Renal Insuffici... Liver Disease Neoplasms | Azacitidine Pevonedistat Docetaxel Paclitaxel Carboplatin | 18 Years - | Takeda | |
| Health Counseling and Exercise in Patients With Acute Leukemia - Pilot Study | NCT01557686 | Acute Leukemia | Health counseli... | 18 Years - | Universitetshospitalernes Center for Sygepleje | |
| MB-dNPM1-TCR.1 in Relapsed/Refractory AML | NCT06424340 | Leukemia, Myelo... | MB-dNPM1-TCR.1 | 18 Years - | Miltenyi Biomedicine GmbH | |
| Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old | NCT04687761 | Leukemia, Myelo... De Novo Age More 60yr | Azacitidine Venetoclax Quizartinib Cytarabine Venetoclax Quizartinib | 60 Years - | PETHEMA Foundation | |
| Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and Thymoglobulin | NCT00915811 | Myelodysplastic... Leukemia, Myelo... | Fludarabine Busulphan Thymoglobuline ... Haematopoietic ... | 18 Years - | King's College Hospital NHS Trust | |
| Unrelated Double Umbilical Cord Blood Units Transplantation | NCT01015742 | Leukemia, Myelo... Leukemia, Lymph... Leukemia, Myelo... | Stem cell Trans... | 1 Year - 50 Years | Tehran University of Medical Sciences | |
| Post-transplant Flotetuzumab for AML | NCT05506956 | Leukemia, Myelo... | Flotetuzumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy | NCT02670044 | Leukemia, Myelo... | Cobimetinib Idasanutlin Venetoclax | 18 Years - | Hoffmann-La Roche | |
| An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) | NCT02610777 | Myelodysplastic... Leukemia, Myelo... Leukemia, Myelo... | Azacitidine Pevonedistat | 18 Years - | Takeda |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
